BR112019023109A2 - Composto, composição farmacêutica e método para tratar uma doença, distúrbio, síndrome ou afecção mediada por nadph oxidase em um indivíduo - Google Patents
Composto, composição farmacêutica e método para tratar uma doença, distúrbio, síndrome ou afecção mediada por nadph oxidase em um indivíduo Download PDFInfo
- Publication number
- BR112019023109A2 BR112019023109A2 BR112019023109-9A BR112019023109A BR112019023109A2 BR 112019023109 A2 BR112019023109 A2 BR 112019023109A2 BR 112019023109 A BR112019023109 A BR 112019023109A BR 112019023109 A2 BR112019023109 A2 BR 112019023109A2
- Authority
- BR
- Brazil
- Prior art keywords
- nadph oxidase
- mediated
- affection
- syndrome
- disorder
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 102000004722 NADPH Oxidases Human genes 0.000 title abstract 3
- 108010002998 NADPH Oxidases Proteins 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 230000001404 mediated effect Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 208000035475 disorder Diseases 0.000 title 1
- 208000011580 syndromic disease Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 abstract 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 abstract 1
- 229930024421 Adenine Natural products 0.000 abstract 1
- 102000004316 Oxidoreductases Human genes 0.000 abstract 1
- 108090000854 Oxidoreductases Proteins 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- 229960000643 adenine Drugs 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 150000002391 heterocyclic compounds Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229960003966 nicotinamide Drugs 0.000 abstract 1
- 235000005152 nicotinamide Nutrition 0.000 abstract 1
- 239000011570 nicotinamide Substances 0.000 abstract 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
o presente pedido se refere a compostos de heteroarila e heterocíclicos fundidos substituídos úteis como inibidores de fosfato dinucleotídico de adenina de nicotinamida oxidase (inibidores de nadph oxidase), processos para sua preparação, composições farmacêuticas que compreendem os compostos, e o uso dos compostos ou das composições no tratamento ou prevenção de várias doenças, afecções e/ou distúrbios mediados por nadph oxidase.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201721015787 | 2017-05-04 | ||
IN201721015787 | 2017-05-04 | ||
PCT/IB2018/053121 WO2018203298A1 (en) | 2017-05-04 | 2018-05-04 | Substituted bicyclic heterocyclic compounds as nadph oxidase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112019023109A2 true BR112019023109A2 (pt) | 2020-05-26 |
Family
ID=62245373
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112019023109-9A BR112019023109A2 (pt) | 2017-05-04 | 2018-05-04 | Composto, composição farmacêutica e método para tratar uma doença, distúrbio, síndrome ou afecção mediada por nadph oxidase em um indivíduo |
Country Status (16)
Country | Link |
---|---|
US (1) | US20200247800A1 (pt) |
EP (1) | EP3619209A1 (pt) |
JP (1) | JP2020518624A (pt) |
KR (1) | KR20200013665A (pt) |
CN (1) | CN110914263A (pt) |
AU (1) | AU2018262528A1 (pt) |
BR (1) | BR112019023109A2 (pt) |
CA (1) | CA3062185A1 (pt) |
CL (1) | CL2019003107A1 (pt) |
CO (1) | CO2019013655A2 (pt) |
EA (1) | EA201992343A1 (pt) |
MX (1) | MX2019013148A (pt) |
PE (1) | PE20191789A1 (pt) |
PH (1) | PH12019502462A1 (pt) |
SG (1) | SG11201910172VA (pt) |
WO (1) | WO2018203298A1 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022508523A (ja) * | 2018-10-01 | 2022-01-19 | ジェンザイム・コーポレーション | UDPグリコシルトランスフェラーゼ阻害剤としてのチエノ[3,2-b]ピリジン誘導体および使用の方法 |
CN115215767B (zh) * | 2021-04-16 | 2023-09-12 | 帕潘纳(北京)科技有限公司 | 制备2-氰基-3-乙氧基丙烯酸乙酯衍生物的方法 |
CN113292496B (zh) * | 2021-05-17 | 2023-03-10 | 安徽联创生物医药股份有限公司 | 一种劳拉替尼中间体的合成方法 |
WO2023217764A1 (en) | 2022-05-09 | 2023-11-16 | Calliditas Therapeutics Suisse Sa | Nox inhibitors for use in the treatment of alport syndrome |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1616576A4 (en) * | 2003-04-08 | 2010-02-10 | Mitsubishi Tanabe Pharma Corp | SPECIFIC NAD (P) H OXIDASE INHIBITOR |
JP2007133750A (ja) * | 2005-11-11 | 2007-05-31 | Canon Inc | 情報処理方法及び情報処理装置 |
EP2002835A1 (en) | 2007-06-04 | 2008-12-17 | GenKyo Tex | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
FR2929276B1 (fr) * | 2008-04-01 | 2010-04-23 | Servier Lab | Nouveaux derives de diosmetine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
EP2165707A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
EP2166009A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as nadph oxidase inhibitors |
EP2166008A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
EP2166010A1 (en) * | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
GB201104600D0 (en) * | 2011-03-18 | 2011-05-04 | Pronoxis Ab | New compounds and medical uses |
ES2870037T3 (es) * | 2015-11-25 | 2021-10-26 | Effector Therapeutics Inc | Compuestos inhibidores de EIF4-A y métodos relacionados con los mismos |
-
2018
- 2018-05-04 MX MX2019013148A patent/MX2019013148A/es unknown
- 2018-05-04 PE PE2019002276A patent/PE20191789A1/es unknown
- 2018-05-04 BR BR112019023109-9A patent/BR112019023109A2/pt not_active Application Discontinuation
- 2018-05-04 JP JP2019560286A patent/JP2020518624A/ja active Pending
- 2018-05-04 AU AU2018262528A patent/AU2018262528A1/en not_active Abandoned
- 2018-05-04 US US16/610,351 patent/US20200247800A1/en not_active Abandoned
- 2018-05-04 EP EP18727437.8A patent/EP3619209A1/en not_active Withdrawn
- 2018-05-04 EA EA201992343A patent/EA201992343A1/ru unknown
- 2018-05-04 CA CA3062185A patent/CA3062185A1/en not_active Abandoned
- 2018-05-04 SG SG11201910172V patent/SG11201910172VA/en unknown
- 2018-05-04 WO PCT/IB2018/053121 patent/WO2018203298A1/en unknown
- 2018-05-04 KR KR1020197035127A patent/KR20200013665A/ko unknown
- 2018-05-04 CN CN201880044473.8A patent/CN110914263A/zh active Pending
-
2019
- 2019-10-29 CL CL2019003107A patent/CL2019003107A1/es unknown
- 2019-10-31 PH PH12019502462A patent/PH12019502462A1/en unknown
- 2019-12-03 CO CONC2019/0013655A patent/CO2019013655A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CN110914263A (zh) | 2020-03-24 |
EA201992343A1 (ru) | 2020-04-16 |
SG11201910172VA (en) | 2019-11-28 |
KR20200013665A (ko) | 2020-02-07 |
CO2019013655A2 (es) | 2020-04-01 |
PH12019502462A1 (en) | 2020-06-29 |
CL2019003107A1 (es) | 2020-03-13 |
US20200247800A1 (en) | 2020-08-06 |
AU2018262528A1 (en) | 2019-11-21 |
MX2019013148A (es) | 2019-12-18 |
JP2020518624A (ja) | 2020-06-25 |
EP3619209A1 (en) | 2020-03-11 |
WO2018203298A1 (en) | 2018-11-08 |
PE20191789A1 (es) | 2019-12-24 |
CA3062185A1 (en) | 2018-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112019023109A2 (pt) | Composto, composição farmacêutica e método para tratar uma doença, distúrbio, síndrome ou afecção mediada por nadph oxidase em um indivíduo | |
BR112017022604A2 (pt) | composto, composição farmacêutica, uso de um composto e de uma combinação, e, combinação | |
BR112018075734A2 (pt) | composto, composição farmacêutica, método para tratar um paciente com uma doença ou condição mediada pelo menos em parte por fxr, e, uso de um composto. | |
BR112018071408A2 (pt) | “composto inibidor de rip2 quinase, composição farmacêutica, usos de um composto e de uma combinação, e, combinação | |
BR112021022457A2 (pt) | Inibidores de fgfr e métodos de uso dos mesmos | |
NO20090723L (no) | Kondenserte heterosykliske derivater og fremgangsmater for anvendelse | |
BR112018007977A2 (pt) | inibidores de ferroportina inovadores | |
BR112015028879A8 (pt) | compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos | |
BR112015023948A2 (pt) | composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer | |
BRPI0808824B8 (pt) | derivado de pirazol piridina como inibidores de nadph oxidase, composição farmacêutica, e, uso de um derivado de pirazol piridina | |
BR112015021888A8 (pt) | inibidores de dna-pk, seus usos e composição farmacêutica | |
BR112015016793A2 (pt) | compostos de tiazolacarboxamidas e piridinacarbo-xamida úteis como inibidores de quinase pim | |
BR112017002221A2 (pt) | 2-(morfolin-4-il)-1,7-naftiridinas | |
BR112018068640A2 (pt) | derivados de indolina substituídos como inibidores da replicação viral do dengue | |
BR112014018990A8 (pt) | Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção | |
BR112019003557A2 (pt) | derivados de oxopicolinamida, método de preparação dos mesmos e uso farmacêutico dos mesmos | |
BR112016020199A8 (pt) | composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso | |
BR112012027034A2 (pt) | inibidores da arginase e suas aplicações terapêuticas | |
BR112017012846A2 (pt) | derivados do amino tiadiazol como inibidores da nadph oxidase. | |
BR112016028876A2 (pt) | composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos. | |
BR112017010645A2 (pt) | derivados da piridinocarboxamida, método de preparação dos mesmos e usos farmacêuticos dos mesmos | |
BR112012020736A2 (pt) | derivados de pirazolo diperidina como inibidores de nadph oxidase. | |
BR112022001324A2 (pt) | Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo | |
BR112017004173A2 (pt) | composto, composição farmacêutica, e, método para tratar uma doença ou condição patológica. | |
BR112016028845A2 (pt) | composto, composição farmacêutica e uso de um composto |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |